文献速递消化道肿瘤放疗放疗物理与技术

自适应MRI引导立体定向体部放疗治疗局部晚期胰腺癌——一项II期研究

Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study.
PubMed 文献 · Radiother Oncol · 2024-05-28

这项前瞻性单中心II期研究纳入28例经组织学或细胞学证实、接受联合化疗超过2个月且无进展迹象的胰腺腺癌患者,处方50-60 Gy分5-8次;2019年起采用1.5 T MRI-linac在线MR图像引导并每日调整计划。主要终点为切除率,6例(21%)接受切除;中位无进展生存7.8个月,中位总生存16.5个月;6例发生III级治疗相关不良事件,初始标准直线加速器组4例中1例发生IV级十二指肠穿孔。

要点

  • 28例局部晚期胰腺癌患者接受50-60 Gy分5-8次SBRT,6例(21%)接受切除。
  • 中位无进展生存7.8个月(95%CI 5.0-14.8),中位总生存16.5个月(95%CI 10.7-22.6)。
  • 6例发生III级治疗相关不良事件;标准直线加速器组4例中1例发生IV级十二指肠穿孔。

核心结论

  • 本研究表明,局部晚期胰腺癌患者接受SBRT与有前景的总生存和切除率相关,且SBRT安全、耐受良好,严重毒性有限。

研究设计与样本

  • 前瞻性单中心II期研究(NCT03648632),招募组织学或细胞学证实的胰腺腺癌患者,要求联合化疗超过2个月且无进展迹象。
  • 共纳入28例患者,2018年8月至2022年3月入组,诊断时均不可切除。
  • 处方剂量50-60 Gy分5-8次;初始4例在标准直线加速器治疗,2019年起在1.5 T MRI-linac上采用在线MR图像引导,治疗计划根据当日解剖调整。
  • 主要终点为切除率。

主要发现

  • 自入组起中位随访28.3个月(95%CI 24.0-NR)。
  • 自入组起中位无进展生存7.8个月(95%CI 5.0-14.8),中位总生存16.5个月(95%CI 10.7-22.6)。
  • 6例(21%)接受切除,另有1例被提供切除但拒绝。
  • 6例发生III级治疗相关不良事件(黄疸、恶心、呕吐和/或便秘)。
  • 初始4例标准直线加速器治疗患者中1例发生IV级十二指肠穿孔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiotherapy (SBRT) has emerged as a promising new modality for locally advanced pancreatic cancer (LAPC). The current study evaluated the efficacy and toxicity of SBRT in patients with LAPC (NCT03648632). METHODS: This prospective single institution phase II study recruited patients with histologically or cytologically proven adenocarcinoma of the pancreas after more than two months of combination chemotherapy with no sign of progressive disease. Patients were prescribed 50-60 Gy in 5-8 fractions. Patients were initially treated on a standard linac (n = 4). Since 2019, patients were treated using online magnetic resonance (MR) image-guidance on a 1.5 T MRI-linac, where the treatment plan was adapted to the anatomy of the day. The primary endpoint was resection rate. RESULTS: Twenty-eight patients were enrolled between August 2018 and March 2022. All patients had non-resectable disease at time of diagnosis. Median follow-up from inclusion was 28.3 months (95 % CI 24.0-NR). Median progression-free and overall survival from inclusion were 7.8 months (95 % CI 5.0-14.8) and 16.5 months (95 % CI 10.7-22.6), respectively. Six patients experienced grade III treatment-related adverse events (jaundice, nausea, vomiting and/or constipation). One of the initial four patients receiving treatment on a standard linac experienced a grade IV perforation of the duodenum. Six patients (21 %) underwent resection. A further one patient was offered resection but declined. CONCLUSION: This study demonstrates that SBRT in patients with LAPC was associated with promising overall survival and resection rates. Furthermore, SBRT was safe and well tolerated, with limited severe toxicities.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Weisz Ejlsmark M, Bahij R, Schytte T, et al. Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study. Radiother Oncol. 2024. PMID: 38815694. doi:10.1016/j.radonc.2024.110347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。